 |
3-[3-(6-guanidino-1-oxoisoindolin-2yl) propanamido]-3-(pyridine-3yl) propanoic acid dihydrochloride |
|---|---|
| Trade Name | Ocurin |
| Orphan Indication | Retinopathy of prematurity |
| USA Market Approval | USA |
| USA Designation Date | 2017-01-17 00:00:00 |
| Sponsor | Advanced Imaging Projects, LLC;7947 Brookside Ct.;Lake Worth, Florida, 33467 |
